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After injury, the CNS undergoes an astrocyte stress response characterized by reactive astrocytosis/proliferation, boundary formation,
and increased glial fibrillary acidic protein (GFAP) and chondroitin sulfate proteoglycan (CSPG) expression. Previously, we showed that
in vitroastrocytes exhibit this stress responsewhen in contactwithSchwanncells butnotolfactory ensheathing cells (OECs). In this study,
we confirm this finding in vivo by demonstrating that astrocytes mingle with OECs but not Schwann cells after injection into normal
spinal cord. We show that Schwann cell-conditioned media (SCM) induces proliferation in monocultures of astrocytes and increases
CSPG expression in a fibroblast growth factor receptor 1 (FGFR1)-independent manner. However, SCM added to OEC/astrocyte cocul-
tures induces reactive astrocytosis and boundary formation, which, although sensitive to FGFR1 inhibition, was not induced by FGF2
alone. Addition of heparin toOEC/astrocyte cultures induces boundary formation,whereas heparinase or chlorate treatment of Schwann
cell/astrocyte cultures reduces it, suggesting that heparan sulfate proteoglycans (HSPGs) are modulating this activity. In vivo, FGF2 and
FGFR1 immunoreactivity was increased over grafted OECs and Schwann cells compared with the surrounding tissue, and HSPG immu-
noreactivity is increased over reactive astrocytes bordering the Schwann cell graft. These data suggest that components of the astrocyte
stress response, including boundary formation, astrocyte hypertrophy, and GFAP expression, are mediated by an FGF family member,
whereas proliferation and CSPG expression are not. Furthermore, after cell transplantation, HSPGsmay be important for mediating the
stress response in astrocytes via FGF2. Identification of factors secreted by Schwann cells that induce this negative response in astrocytes
would further our ability to manipulate the inhibitory environment induced after injury to promote regeneration.
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Introduction
After CNS injury, a series of cellular and molecular events de-
velop over several days, culminating in the formation of a glial
scar. Many cell types contribute to this scar, but astrocytes pre-
dominate (Fawcett and Asher, 1999). These astrocytes become
activated in response to injury and undergo numerous cytologi-
cal and biochemical changes ranging from increased synthesis of
glial fibrillary acidic protein (GFAP), chondroitin sulfate proteo-
glycans (CSPGs), growth factors, and enzymes to increase prolif-
eration (Eng et al., 1994; Norenberg, 1994; McKeon et al., 1999).
Their most dramatic response is seen in the formation of the glial
scar accompanied by extensive hypertrophy of their cell body and
cytoplasmic processes. The formation of this scar is thought to
isolate areas of tissue necrosis and exclude non-neural cells from
theCNSparenchyma filling the tissue cavity resulting from injury
(Eddleston and Mucke, 1993). In the context of CNS injury, this
astrocytic response also prevents axonal regeneration (Silver and
Miller, 2004; Pekny and Nilsson, 2005). The search for the initial
molecular inducer of inhibitory astrocytosis/gliosis is ongoing.
In this context, the relative merits of two types of candidate
transplant cells, Schwann cells (SCs) and olfactory ensheathing
cells (OECs), require evaluation regarding their capacity to in-
duce the astrocyte stress response. Both OECs and Schwann cells
have been widely advocated for transplant-mediated repair of
CNS lesions (Doucette, 1995; Franklin and Barnett, 2000; Rais-
man, 2001; Chuah andWest, 2002;Wewetzer et al., 2002; Barnett
andChang, 2004; Ruitenberg et al., 2006). Although it is apparent
that both cell types offer advantages for promoting repair (Xu et
al., 1995; Li et al., 1997; Ramon-Cueto et al., 1998; Pearse et al.,
2004a), there is much debate as to which is the preferred candi-
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date (Takami et al., 2002; Garcia-Alias et al., 2004; Pearse et al.,
2004b; Barnett and Riddell, 2004; Riddell et al., 2004).
OECs and Schwann cells havemany similarities, sharing com-
mon growth factor responses (Dong et al., 1997; Pollock et al.,
1999), antigenic and morphological characteristics (Ramon-
Cueto and Valverde, 1995; Franceschini and Barnett, 1996), and
transcriptional regulation (Smith et al., 2001). However, a dis-
tinct difference between OECs and Schwann cells is their con-
trasting ability to induce the reactive astrocyte response in vitro
(Lakatos et al., 2000; Fairless et al., 2005) and in vivo (Plant et al.,
2001; Lakatos et al., 2003). In previous studies, using assays de-
vised to observe the inhibitory interactions between Schwann
cells and astrocytes (Ghirnikar and Eng, 1994;Wilby et al., 1999),
we demonstrated that Schwann cells and astrocytes occupied dis-
tinct, nonoverlapping areas in coculture, termed boundary for-
mation (Lakatos et al., 2000). Furthermore, astrocytes in contact
with Schwann cells became hypertrophic with an increase in cy-
toplasmic area and increased expression of bothGFAP andCSPG
(Wu et al., 1998; Lakatos et al., 2000). In contrast, OECs and
astrocytes frequently intermingled in the same area and did not
induce astrocyte hypertrophy.
The mechanisms underlying these differences are not known.
Here, we show that the reactive astrocyte phenotype can be in-
duced by OECs if factor(s) secreted by Schwann cells are intro-
duced. Our data suggest that this factor is likely to belong to the
fibroblast growth factor (FGF) family, because inhibition of FGF
receptor 1 (FGFR1) promoted cell mingling in OECs/astrocyte
cultures treated with Schwann cell-conditioned media (SCM).
Furthermore, OECs cannot activate astrocytes by FGF2 unless
heparin is added, and Schwann cell/astrocyte cultures can be in-
duced to mingle if treated with heparinase or chlorate. This sug-
gests that heparan sulfate proteoglycans (HSPGs) are necessary
for this aspect of the stress response. Injections of green fluores-
cent protein (GFP)-expressing OECs and Schwann cells into the
normal spinal cord show similar differences in their ability to
coexist with astrocytes. In addition, increased levels of HSPG
were detected in astrocyte processes bordering the Schwann cell
graft, supporting the physiological relevance of the observations
made in vitro. These results add to the accumulating data that
OECs are distinct from Schwann cells and may have advantages
over them for transplant-mediated repair of CNS injury because
their HSPGprofile induces a less-severe astrocyte stress response.
Materials andMethods
Generation of purified glial cells. Astrocytes, OECs, and Schwann cells
were purified as described previously (Lakatos et al., 2000) and main-
tained on poly-L-lysine (PLL; 13.3 g/ml; Sigma-Aldrich, Dorset, UK)-
coated flasks. Astrocytes were maintained in DMEM containing 10%
fetal bovine serum (FBS) (DMEM-FBS; Autogen Bioclear, Wiltshire,
UK). Fluorescence-activated cell sorting (FACS)-purified OECs were
cultured in serum-freemodifiedDMEM(DMEM-BS) (Bottenstein et al.,
1979; Barnett et al., 1993) with 5% FBS and further supplemented with
FGF2 (500 ng/ml; Peprotech, London, UK), heregulin -1 (Hrg1; 50
ng/ml; R&D Systems, Abingdon, UK), forskolin (5  107 M; Sigma-
Aldrich), and astrocyte conditioned medium (ACM) (Noble and Mur-
ray, 1984), which has been shown to be a potent mitogen for promoting
prolonged growth of p75 neurotrophin receptor (p75NTR)-expressing
OECs (Alexander et al., 2002). Schwann cells were maintained in
DMEM-FBS containing forskolin (106 M) and Hrg1 (20 ng/ml; R&D
Systems).
Confrontation assay.This assaywas performed as described byWilby et
al. (1999) and Lakatos et al. (2000). Briefly, 10l strips containing 10,000
cells of eitherOECs or Schwann cells were set up opposing a parallel 10l
strip containing 10,000 astrocytes on a PLL-coated coverslip. Cells were
allowed to attach for 1 h before washing in DMEM-FBS to remove non-
attached cells. Cultures were then maintained in DMEM-FBS and al-
lowed to grow toward each other over a period of 12–14 d, giving time for
cells to make contact and interact (Lakatos et al., 2000). In some experi-
ments, growth factor receptor inhibitors, heparin, chlorate, or hepari-
nase were added to the cultures after the cells had contacted each other.
Cultureswere then immunolabeled for astrocytes using anti-GFAP [anti-
rabbit (Dako, Ely, UK) or anti-mouse IgG1 (Sigma-Aldrich)] and for
OECs and Schwann cells using anti-p75NTR [1:1; IgG1; hybridoma su-
pernatant (Yan and Johnson, 1988) or anti-rabbit (Abcam, Cambridge,
UK)]. Using NIH Image J, a 300 m line was drawn along the interface
between astrocytes and either OECs or Schwann cells (see Fig. 1Aiii,Aiv).
The numbers of OECs or Schwann cells crossing the cell:cell boundary
were counted and averaged over five randomly chosen fields. Fields are
variable, and strong boundaries are not always seen if the two cell popu-
lations have not met in the allotted time. However, in general we see
many areas inwhich clear boundaries aremade in astrocyte/Schwann cell
cultures. Experiments were repeated at least three times.
Coculture assay. In some cases, cocultures were used when measure-
mentsweremade of astrocyte area andGFAP expression or larger contact
areas were needed forWestern blot analysis. Astrocyte:OEC and astrocy-
te:Schwann cell cocultures were performed by mixing either OECs or
Schwann cells with astrocytes at a ratio of 3:1. Primary cultures were
generally maintained for 2–6 weeks before setting up the assays. Cells
were mixed in suspension at a total cell number of 4 103 per well and
then added to PLL-coated coverslips in 24-well plates containing 500 l
of DMEM-FBS. Alternatively, for creating cell lysates, a total cell number
of 1.6 104 was added to each well of a six-well plate, containing 2ml of
DMEM-FBS. These cultures were maintained for 14 d [for hypertrophy
analysis, by which time an astrocytic response had occurred (Eng and
Ghirnikar, 1994; Lakatos et al., 2000)]. After this time, cultures grown on
coverslips in 24wells were fixed and immunolabeled, and cultures grown
in 6-well plates were lysed for immunoblotting.
Collection of SCM, OEC-conditioned medium, and ACM. When cul-
tures of purified Schwann cells or OECs in T25 (cm2) flasks were con-
fluent (maintained in vitro for 2–6 weeks), they were rinsed twice with
PBS and 4ml of DMEM-BSwithout growth factors added. Cultures were
maintained for an additional 2 d before medium collection, which was
centrifuged to remove cell debris, and filtrated through a 0.2 m filter
(Millipore, Hertfordshire, UK). Exactly the same procedure was used for
generating ACM, apart from confluent astrocyte cultures were main-
tained inT75 (cm2) flasks, towhich 10ml ofDMEM-BSwas added. SCM
and OEC-conditioned medium (OCM) were added to cell cultures at a
1:1 ratio with DMEM-FBS, except for proliferation studies, in which
media were titrated with DMEM-BS.
Treatment of confrontation assays by SCM, heparin, heparinase, or
chlorate. Confrontation assays were set up as described above until the
cells were in contact. In OEC/astrocyte cultures, the medium was re-
placed with SCM/DMEM-FBS (1:2) or with DMEM-FBS containing 10
g/ml heparin (Sigma-Aldrich). In Schwann cell/astrocyte cultures, 5
mM chlorate [Sigma-Aldrich; dissolved inRPMI (Roswell ParkMemorial
Institute) medium containing 10% FBS (Invitrogen, Paisley, UK)] or 5
U/ml heparinases I, II, and III (Sigma-Aldrich)were added. Both cultures
were treated for 2 d, and heparin and heparinasewere reapplied every day
and then immunolabeled as described above.
Digestion of SCM. SCM was digested to assess whether its activity was
proteinaceous in nature. SCM (2 ml) was incubated with 100 l of
trypsin-agarose bead suspension (50:50 suspension beads to PBS; 2.5 U;
Sigma-Aldrich) left to digest for 24 h at 37°C on a rotating platform and
then collected after centrifugation. The digested SCM was then filtered
through a 0.22 m syringe filter (Millipore) and tested in the various
assays.
Inhibitor treatment. Inhibitors of various tyrosine receptor kinases and
an inhibitor of the nonreceptor tyrosine kinase Src were added to the
confrontation assays. These include epidermal growth factor receptor
(EGFR; AG1478; 300 nM;Merck Biosciences, Nottingham,UK), platelet-
derived growth factor receptor [PDGFR; 6,7-dimethyl-2-phenyl-
quinoxaline (AG1295); 10 M; Merck Biosciences], FGFR1 (3-[3-(2-
carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone (SU5402); 10
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M; Merck Biosciences), and the Src inhibitor
(SU6656; 10 M; Merck Biosciences). The
EGFR inhibitor [4-(3-chloroanilino)-6,7-
dimethoxyquinazoline] is a very potent and se-
lective inhibitor of epidermal growth factor re-
ceptor kinase (Liu et al., 1999). The PDGFR
inhibitor selectively inhibits PDGF receptor ki-
nase (Kovalenko et al., 1994). The FGFR inhib-
itor selectively inhibits the tyrosine kinase ac-
tivity of FGFR1 with little cross-reactivity to
PDGFR or EGFR (Mohammadi et al., 1997).
SU6656, a Src family kinase inhibitor, inhibits
Src as well as closely related kinases such as Fyn,
Yes, and Lyn. It acts as a weak inhibitor of Lck
and PDGF receptor kinase (Blake et al., 2000).
Controls included DMEM-FBS and SCM without the addition of inhib-
itors. Inhibitors were added to the cells at the same time as SCM, which
was on day 10 of coculture between the various glial cells. After 2 d,
cultures were immunolabeled with antibodies to GFAP (astrocytes) and
p75NTR (OECs).
ELISA assay for FGF2. An ELISA assay was performed using condi-
tioned medium prepared by omitting bovine serum albumin from the
DMEM-BSmix, which was incubated on confluent cultures of astrocytes
(ACM), OECs (OCM), and Schwann cells (SCM) for 48 h. FGF2 levels
were estimated using a commercial ELISA kit (the Quantikine HS Im-
munoassay kit; R&D Systems) following the manufacturer’s instruc-
tions. The assay was repeated three times with different sources of con-
ditioned medium.
Expression of mRNA for FGF receptors. To check for the presence of
all four FGFR mRNAs in astrocytes, OEC and Schwann cell reverse
transcription (RT)-PCR was carried out. Briefly, RNA was prepared
from the three cell types using RNA-Bee isolation reagent (AMS Bio-
technology, Oxon, UK) and chloroform following the manufacturer’s
protocol. The RNA was precipitated with isopropanol and resus-
pended in water. Primers for FGFR1–FGFR4 (Table 1) were synthe-
sized by Sigma-Genosys orMWGBiotech (London, UK) resuspended
in water and used at 0.1 g/l. For the reverse transcription, a master
mix containing random primers (250 ng/l), RNA (2 g), and dNTP
(10 mM; Invitrogen) was incubated at 65°C for 5 min quenched on ice
and spun briefly. A second master mix containing 5 first strand
buffer (Invitrogen), DTT (0.1 M; Invitrogen), and RNase Out (40 U;
Invitrogen) was added, and the samples were incubated at 25°C for 2
min. After the addition of SuperScript II reverse transcriptase (200 U;
Invitrogen), the samples were incubated at 25°C for 10 min and at
42°C for 50 min. The reaction was terminated at 70°C for 15 min. The
cDNAs were amplified using primers for each FGFR isoform. Rat
brain cDNAs and cyclophilin were used as controls. The PCR was
performed using two protocols. The first, for FGFR1IIIc, FGFR2IIIC,
and FGFR3IIIC, was set at 94°C for 3 min, 30 cycles of 94°C for 30 s,
54°C for 30 s, 72°C for 30 s, and 72°C for 5 min (Kirby et al., 2003).
The second protocol, for FGFR1IIIB, FGFR2IIIB, FGFR3IIIB, and
FGFR4, was identical apart from an annealing temperature of 58°C.
Adhesion assay. Cells were labeled with Vybrant [Vybrant CFDA SE
(carboxyfluorescein diacetate, succinimidyl ester) Cell Tracer Kit; In-
vitrogen] by incubating with Vybrant diluted in PBS (1:500) for 15 min,
followed by washing in 1% DMEM-BS. Labeled cells (20,000 Schwann
cells or OECs) were then plated onto PLL-coated coverslips previously
grown to confluency as a monolayer of astrocytes. After 30 min at 37°C
with gentle shaking, coverslips were removed, washed three times in
Hanks staining medium (Invitrogen) and then fixed in 3.7% formalde-
hyde for 10min. The number ofVybrant-labeled cells remaining adhered
to the coverslip was then counted. All experiments were performed in
duplicate and performed thrice.
Time-lapse video microscopy. Speeds of migrating cells were measured
using time-lapsemicroscopy. OECs or Schwann cells were plated at a low
density (10,000 per coverslip) on either PLL-coated coverslips or cover-
slips containing confluent astrocyte monolayers and left to adhere over-
night. Images were then taken every 20 min for 3 h using the Open Lab
Time-lapse Video Microscopy System. Distances moved by individual
cells were measured and averaged over approximately five cells per ex-
periment. Experiments were performed in duplicate and performed
thrice.
Antibodies. For FACS purification, hybridoma supernatants were used
againstO4 (IgM) (Sommer and Schachner, 1981) andGalC (IgG3) (Ran-
scht et al., 1982) at a dilution of 1:1.
For immunocytochemistry, hybridoma supernatants were used
against p75NTR (IgG1) (Yan and Johnson, 1988) at a dilution of 1:1. Both
hybridoma supernatants were collected from a confluent monolayer of
the hybridoma cells. The following primary antibodies were also used,
anti-GFAP [anti-rabbit (Dako); anti-mouse IgG1 (Sigma-Aldrich)] at
1:100, anti-p75NTR (anti-rabbit; Abcam), anti-bromodeoxyuridine
(BrdU; IgG1; Dako) at 1:20, and anti-neurocan (IG2; IgG) (Oohira et al.,
1994) at 1:20. In addition, the pan anti-CSPGs, CS-56 (Sigma-Aldrich;
IgM) at 1:100, and 473HD, which recognizes the DSD-1 epitope embed-
ded in the CS side chains (IgM) (Faissner et al., 1994) at 1:25, were used.
Class-specific fluorophore-conjugated antibodies were diluted 1:100
(Southern Biotechniques; Cambridge Bioscience, Cambridge, UK).
For immunoblotting, the following antibodies were used: anti-
vinculin (IgG; BDBiosciences, San Jose, CA) at 1:1000, anti-GFAP (IgG1;
Figure 1. SCM induces boundary formation in OEC/astrocyte confrontation assays. Confron-
tation assays between astrocytes and OECs were set up in DMEM-FBS (FBS; Ai, Aiii), and be-
tween day 10–14 experimental cultures were switched to DMEM-FBS containing 50% SCM
(Aii,Aiv). After 2 d, clear boundaries could be seen between astrocytes (AS) and OECs after SCM
addition (white arrows). Ai, Aii, Phase image. Aiii, Aiv, Immunocytochemistry with p75 NTR
(OECs; green) andGFAP (astrocytes; red). The yellow line illustrates a typical 300mlinedrawn
to quantify the number of cells that cross the boundary between the astrocytes and either OECs
(Aiii) or Schwann cells. OECs or Schwann cells would be counted below the line. Scale bars, 200
m.
Table 1. Primer pairs used for PCR amplification
Receptor Forward primer Reverse primer
FGFR1IIIB 5-CTCGGATGCGGAGGTGCT GA-3 5-GCACAGGTCTGGTGACAG TGA-3
FGFR1IIIC 5-GGT GCTTCA TCTACGGAATGTCTCC-3 5-TCAGAGACGCCAGCTAGCATGG-3
FGFR2IIIB 5-CCAGGATGGACC CCTCTA TGTCA-3 5-TGCAGTTGGTGGGCTTGT CCA-3
FGFR2IIIC 5-GGAATGTAA CTT TTGAGGACGCTGG-3 5-GAT GTC TCCCGTTGAGGAAAGACG-3
FGFR3IIIB 5-GATCAGTGAGAA TGTGGAGGCAGA-3 5-TTGGGG CCCGTGAACACGAA-3
FGFR3IIIC 5-ACA CCACCGACAGGGAGCTAGAGG-3 5-CTT GTCGATGTT CTTGTGTCTTCCG-3
FGFR4 5-AGC TATCTG CTGGATGTGCTGGA-3 5-TTC TGTACAGTGACAGGC TGTCGA-3
The FGFRB series primers were designed using GeneFischer interactive primer design program. The FGFRC primer sequences were taken from the literature
(Kirby et al., 2003).
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Sigma-Aldrich) at 1:1000, and anti-neurocan (IG2 antibody; IgG) at 1:2.
Secondary antibodies were HRP conjugated (anti-mouse; IgG; Jackson
ImmunoResearch, Suffolk, UK) and used at 1:7000.
Immunocytochemistry for in vitro studies. Immunocytochemistry was
performed on cells plated on PLL-coated coverslips as described previ-
ously (Franceschini and Barnett, 1996; Lakatos et al., 2000). Cells were
fixed in 3.7% formaldehyde for 10 min at room temperature and then
washed in PBS. Permeabilization was performed using 0.5% Triton
X-100/1% BSA in PBS for 15 min at room temperature. After additional
washes in PBS, cells were blocked in 10% FBS in PBS for 30 min at room
temperature. Antibody dilutions were made (as above) in 10% FBS in
PBS and applied for 60 min. After washing with PBS/0.025% Tween 20
(PT), secondary antibodies were added for 45 min, followed by a final
wash and mounting in Vectashield (Vector Laboratories, Peterborough,
UK) supplemented with 4,6-diaminidino-2-phenylindole (DAPI;
Sigma-Aldrich). In some experiments for GFAP immunocytochemistry,
cells were fixed with methanol at 20°C for 15 min before antibody
incubation. Imageswere visualized using anAxioskop fluorescentmicro-
scope (Zeiss, Thornwood, NY) and collected using MetaMorph with a
monochrome camera (Princeton Instruments, Trenton, NJ).
BrdU uptake. Cell proliferation was assayed by measuring the incor-
poration of BrdU (Roche Diagnostics, Mannheim, Germany) during the
S phase of the cell cycle, as described previously (Pollock et al., 1999).
Astrocytes were seeded at low density onto PLL-coated coverslips and left
to adhere overnight. Cells were then treated with SCM dilutions or con-
trolmedium for 12 h before the addition of 20MBrdU, to label dividing
cells, and incubated for an additional 16 h. After this time, cells were fixed
in 100%methanol (20°C for 10min), before 1min incubation in 0.2%
paraformaldehyde at room temperature, followed by 7min of incubation
at room temperature in 0.07 M NaOH. Fixed cells were directly immu-
nolabeled with anti-BrdU antibody for 40 min, followed by the second-
ary IgG1-FITC (1:100) for 30min. The percentage of BrdU-positive cells
was calculated by counting200DAPI-labeled
nuclei at three random sites. Experiments were
performed thrice.
Immunoblotting.Whole cell lysates were pre-
pared using ice-cold lysis buffer (50 mM
HEPES, pH 7.5, 150mMNaCl, 1mMEDTA, 2.5
mM EGTA, 1 mM DTT, 0.1% Tween 20, and
10% glycerol) with inhibitors (1 mM Na-
fluoride, 10 g/ml leupeptin, 20 U/l
aprotinin, 10 mM glycerophosphate, 0.1 mM
Na-orthovanadate, and 0.1 mM phenylmethyl-
sulfonyl fluoride; Sigma-Aldrich). The lysates
were sonicated and spun at 12,000 rpm for 10
min at 4°C, and protein levels of the superna-
tants were estimated using a bicinchoninic acid
assay (Sigma-Aldrich). Fifteen micrograms of
proteins were electrophoresed through a 10%
SDS-containing polyacrylamide gel and blotted
onto a 0.45 mm pore-size nitrocellulose mem-
brane (Millipore) The membrane was incu-
bated in blocking buffer (PT containing 5%
milk powder) for 1 h at room temperature, fol-
lowed by three washes in PT. All primary anti-
bodies were diluted accordingly (see above) in
blocking buffer and incubated overnight at
4°C. After washing three times for 5 min in PT,
the blots were incubated with the appropriate
HRP-conjugated secondary antibody for 30
min at room temperature (1:7000). Blots were
visualized using the enhanced chemilumines-
cence (ECL) detection system (GE Healthcare,
Little Chalfont, UK).
Protein extracts for immunoblotting with
antibodies against the CSPGs were pretreated
with chondroitinase (Sigma) to remove GAG
chains, which can smear the blotting profile
(McKeon et al., 1999; Asher et al., 2000). Chon-
droitinase (0.2 U) was diluted 1:10 with
chondroitinase-activating buffer (50 mM Tris, pH 8.0, 60 mM sodium
acetate, and 0.2% bovine serum albumin) from which 0.02 U/ml was
added to protein extracts, before incubation at 37°C for 3 h.
Assessment of cellular interactions in vivo. Purified OECs and Schwann
cells were generated from 7-d-old Fischer rat pups for transplantation
into adult Fischer rats. The cells weremarked with the reporter gene GFP
by lentiviral infection. Cells were90%GFP positive. Confluent 25 cm3
flasks of both cells were trypsinized and spun, and a cell slurry was gen-
erated to contain between 5  105 and 1  106 cells in 20 l. Three
Fischer adult rats were injected with GFP-expressing OECs and/or GFP-
expressing Schwann cells into the normal spinal cord. Animals were
anesthetized with halothane, and the fourth lumbar spinal segment was
exposed by laminectomy at the T13/L1 vertebral junction. OECs and
Schwann cells were injected at the same rostrocaudal location but on
opposite sides of the spinal cord, such that the two cell types were trans-
planted within the same transverse plane. These sites were located just
lateral to the surface central vein on the left and right sides of the cord and
at an angle of 25° (pipette tip pointingmedially). Pipettes were filled with
1l of a concentrated cell suspension (100,000 cells/l) and inserted
into the dorsal columns at parallel sites. Cells were pressure injected
through beveled glass pipettes (inner tip diameter, 60–70 m).Wounds
were closed in layers, and an analgesic was routinely administered (Vet-
ergesic; 0.06 mg, s.c.; Alstoe, York, UK).
Histological processing. After a survival period of 10 d, animals were
deeply anesthetized with intraperitoneal sodium pentobarbital (Eu-
thatal; 200 mg/ml; Vericore, Dundee, UK) and perfused through the left
ventricle withmammalian Ringer’s solution (containing 0.1% lidocaine)
followed by freshly depolymerized 4% paraformaldehyde in 0.1 M phos-
phate buffer, pH 7.4. A block of tissue encompassing the injection sites
was removed and postfixed overnight in the same fixative with 30%
sucrose. Transverse sections (70m) through the injection sites were cut
Figure2. Both SCMandOEC contact are required for inductionof astrocytic hypertrophy as assessedby astrocyte area andGFAP
immunoreactivity. A, Cultures were generated of astrocytemonolayers alone (control; Ai, Aiv), astrocytes in confrontation assays
with OECs with (Av) or without the addition of SCM (Aii) or SCM and OCM (Avi) or in confrontation assay with Schwann cells as a
positive control (Aiii). The effect of the various culture conditions on astrocytic area was assessed by immunocytochemistry
[astrocytes, GFAP (red); OECs or Schwann cells, p75 NTR (green)]. Hypertrophic astrocytes are indicatedwith awhite asterisk. Scale
bar, 100m.B), Quantification of astrocytic areawas performed usingNIH Image analysis. *p 0.001. Error bars represent SEM.
C, Western blot showing GFAP expression after treatment of astrocytes. Treatments included astrocytes cultured in FBS (control
with no additions), coculturedwith OECs, SCs, 50% SCM, and OECswith 50% SCM treatment (OECsSCM). Vinculinwas used as a
protein loading control.D, Densitometry of GFAP expression, relative to vinculin. GFAPwas upregulated in Schwann cell:astrocyte
cocultures and in OEC:astrocyte cocultures only after treatment with SCM. AS, Astrocytes.
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on a freezing microtome and incubated free-floating for 30 min in 50%
ethanol and then washed for 10 min in 0.3 M PBS. Sections were then
incubated for 72 h at 4°C in combinations of the following primary
antibodies: sheep anti-GFP (1:1000; Biogenesis, Kingston, NH), mouse
anti-GFAP (1:1000; Sigma-Aldrich), rabbit anti-GFAP (1:1000; Dako),
mouse anti-heparan sulfate 10E4 (1:1000; Seikagaku, Tokyo, Japan), rab-
bit anti-FGF-2 (1:100; Millipore), and rabbit anti-FGFR1 (1:200; Santa
Cruz Biotechnology, Santa Cruz, CA). Sections were subsequently incu-
bated in fluorophore-conjugated species-specific donkey IgG secondary
antibodies (or IgM for anti-HSPG) for 4 h at room temperature. All
antibodies were diluted in PBS with 0.3% Triton X-100. Sections were
mounted onto plain glass slides using Vectashield (Vector Laboratories)
and stored at20°C.
Epifluorescence and confocal microscopy. Sections were initially exam-
ined at low power using a Nikon (Tokyo, Japan) Eclipse E600 epifluores-
cence microscope, and sections containing GFP-expressing cells were
examined further using either a Bio-Rad (Hercules, CA) MRC1024 or
Radiance 2100 confocal system. Three-channel serial scans were made
through the full thickness of the stained tissue at low (10 or 20; 2m
steps) and high (40 oil immersion; 0.5m steps) powers. Image stacks
of each fluorescence channel were projected using Confocal Assistant
software (Todd Clark Brelje, University of Minnesota, Minneapolis,
MN) and exported toAdobePhotoshopCS2 version 9.0 (Adobe Systems,
San Jose, CA) for processing for illustration.
Results
SCM induces boundary formation in OEC/astrocyte
confrontation assays
Confrontation assays are commonly used to demonstrate that
Schwann cells are less able than OECs to mingle with astrocytes
and induce characteristics of hypertrophy (Wilby et al., 1999;
Lakatos et al., 2000; Grimpe et al., 2005; Fairless et al., 2005).
Astrocytic hypertrophy is only induced when in contact with
Schwann cells. Here, we confirm that OECs are able to migrate
within astrocytic areas (Fig. 1Ai,Aiii). However, when SCM (di-
luted 1:1 with DMEM-FBS) was added to confrontation assays of
OECs and astrocytes 10 d after initial plating and left for an ad-
ditional 2 d, distinct boundaries formed at the interface between
OECs and astrocytes (Fig. 1Aii,Aiv, arrows), as seen in Schwann
cell and astrocyte confrontation assays (Wilby et al., 1999; Laka-
tos et al., 2000; Fairless et al., 2005). As seen for Schwann cell/
astrocyte confrontation assays, astrocytic hypertrophy only oc-
curs in astrocytes that are in contact withOECs in the presence of
SCM.
SCM and OEC contact with astrocytes is necessary for the
induction of astrocyte hypertrophy as assessed by an increase
in astrocyte area and GFAP expression
To assess whether astrocytes require contact with OECs or
Schwann cells for the induction of astrocytic hypertrophy, we
compared the effect of adding SCM and OCM (diluted 1:1 with
DMEM-FBS) to either astrocytes cultured alone (DMEM-FBS)
or cocultured with OECs or Schwann cells as described previ-
ously (Lakatos et al., 2000; Fairless et al., 2005). Astrocyte hyper-
trophy was assessed bymeasuring changes in astrocyte area using
NIH Image and GFAP expression by immunoblotting. In this
way, cultures were incubated with DMEM-FBS, SCM, or a 1:1
mixture of SCM and OCM (SCMOCM) for 2 d before immu-
nolabeling for GFAP (astrocytes) or p75NTR (OECs or Schwann
cells) (Fig. 2A,B) or immunoblotting for GFAP (Fig. 2C,D).
Astrocyte area and GFAP expression did not change in astro-
cyte cultures treated with SCM (Fig. 2Aiv; C, lane 4). However, if
SCM was added to cocultures of astrocytes with OECs, astrocyte
area increased from 2495 218 to 5438 615m2 ( p 0.001)
(Fig. 2Av) and GFAP expression increased twofold (Fig. 2C, lane
5). In these experiments, astrocyte/Schwann cell cocultures were
used as a positive control (Fig. 2Aiii; C, lane 3). It is possible that
OECs cocultured with astrocytes could also secrete factors that
synergized with SCM to induce astrocyte hypertrophy. For this
reason, astrocyte cultures were treatedwith both SCMandOCM.
Similar to the single factors, combining SCM and OCM did not
have any effect on astrocyte area (Fig. 2Avi; B, lane 6). These
results suggest that induction of hypertrophy in astrocytes as as-
sessed by an increase in astrocyte area and GFAP expression re-
quires both SCM and OEC contact.
SCM did not affect cellular adhesion or migration of OECs
and Schwann cells to astrocyte monolayers
To ensure that SCM did not affect boundary formation by alter-
ing the migration and adhesion properties of OECs or Schwann
cells, we performed time-lapse studies and adhesion assays. Con-
fluent astrocyte cultures were maintained in DMEM-FBS and
then switched to test conditions for 2 d (e.g., SCMorOCM), after
which migration and adhesion assays were performed (Fig. 3).
Vybrant-labeled OECs and Schwann cells were allowed to adhere
to control and SCM-treated astrocyte monolayers overnight, af-
ter which their migration speeds weremeasured using time-lapse
Figure 3. Treatment of astrocyte monolayers with SCM does not affect SC or OEC migration
and adhesion but is mitogenic for astrocytes. A, Migration was measured using time-lapse
microscopy and the average migration speed was calculated [SC, 11.14 2.8m/h (n	 8);
SCSCM, 12.15 2.4 (n	 11); OEC, 20.1 1.7 (n	 16); OECSCM, 17.9 2.2 (n	 12)].
As reported previously, Schwann cell migrationwas significantly slower on astrocytemonolay-
ers than OEC migration. After SCM treatment, there was no change in the observed migration
speeds of either OECs or Schwann cells on astrocytes.B, An adhesion assaywas performedusing
Vybrant-labeled cells to aid detection, which were left to adhere to confluent monolayers of
either astrocytes or OECs/Schwann cells for 30 min. Both OEC and Schwann cell adhesion was
similar after SCM or OCM treatment. C, BrdU incorporation was assessed by indirect immuno-
fluorescence after treatment with DMEM-BS H/F (control growth media) and compared with
the BrdU uptake seen after SCM andOCM treatment. SCM induced a significant increase in BrdU
uptake (*p 0.001).D, SCMwas titrated in DMEM-BS H/F (1:50, 1:10, 1:5, and 1:1), and BrdU
incorporation into astrocyteswasmeasured. SCMcould be titrated to a plateau inwhich40%
of the cells took up BrdU after 16 h of incubation. Cont, Control. *p 0.001. Experiments were
performed three times in duplicate. Error bars represent SEM.
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microscopy. As has been reported previously (Fairless et al.,
2005), Schwann cells migrated at slower speeds than OECs on
astrocyte monolayers (Fig. 3A), demonstrating astrocyte-
induced impairment of Schwann cell migration, compared with
OECs. The treatment of astrocyte monolayers with SCM did not
affect themigration ability of either Schwann cells or OECs. Sim-
ilar comparisons were made using adhesion assays in which
Vybrant-labeled cells were allowed to adhere to astrocyte mono-
layers previously treated for 2 d with DMEM-FBS, SCM, or
OCM, while on a shaking platform. The number of cells that
adhered after 30 min to the astrocyte monolayers was quantified.
The addition of SCM and OCM to astrocyte monolayers did not
significantly affect the ability of either OECs or Schwann cells to
adhere to astrocytes (Fig. 3B).
These data demonstrate that SCM treatment of astrocytes
does not affect the migration and adhesion characteristics of
OECs and Schwann cells, suggesting that there was not a trivial
reason for the boundary formation in the coculture and confron-
tation assays. However, SCM treatment of astrocytes stimulated
their proliferation. Astrocyte proliferation in the presence of
SCM was measured by uptake of BrdU using indirect immuno-
fluorescence 16 h after preincubation with 20M BrdU. Optimal
SCM dilutions were estimated using a concentration–response
assay in which SCM was titrated from 1:50 to 1:1 SCM:
DMEM-BS H/F (serum-free DMEM-BS supplemented with
heregulin and forskolin) (Fig. 3C). A significant proliferative re-
sponse could be detected when SCM was diluted at 1:10 and had
reached a plateau by 1:5. Proliferation was also compared for
astrocytes incubated in OCM, which were diluted 1:1 with
DMEM-BS. DMEM-BS H/F was used as control media because
this is the media used to collect the conditioned media and al-
lowed proliferation changes to be measured without being
masked by the overriding effect of serum. Under these condi-
tions, astrocyte proliferation was unaffected by addition of OCM
butwas increased 2.5-fold by SCM( p 0.001), with the percent-
age of cells taking up BrdU increasing
from 10.2  0.8% to 24.9  3.1% (Fig.
3D).
The activity in SCM is trypsin sensitive
To determine whether the factor in SCM
(collected in serum-free medium) was a
protein, SCM was subjected to trypsin di-
gestion, and the extent of proteolysis was
assessed by SDS-PAGE (Fig. 4A). Al-
though this unknown factor in SCMcould
not be identified on the gel, we were able
to confirm that the trypsin digestion had
worked by comparing brilliant blue
G-colloidal staining of a more prominent
64 kDa protein, identified as transferrin
(confirmed by mass spectrometry). After
trypsin treatment, the intensity of the
transferrin band was significantly re-
duced, producing a fragment of lowermo-
lecular weight. The biological activity of
the digested SCM compared with undi-
gested SCM in OEC/astrocyte confronta-
tion assays was reduced, confirming that a
trypsin-sensitive component of SCM is re-
sponsible for the promotion of boundary
formation (Fig. 4C). Furthermore, trypsin
treatment of SCM reduced its ability to
promote astrocyte proliferation (Fig. 4B).
Fibroblast growth factor receptor inhibition disrupts SCM-
induced boundary formation in OEC astrocyte cultures
To investigate the signaling pathways that might induce boundary
formation between OECs and astrocytes in the presence of SCM,
various tyrosine receptor kinase inhibitors and an inhibitor of the
nonreceptor tyrosine kinase Src were added to the confrontation
assays. These included EGFR (AG1478), PDGFR (AG1295), and
FGFR1 (SU5402). Although these inhibitorsmay nonspecifically af-
fect related receptors, they provide an indication of which growth
factor may be mediating this effect. Controls included incubating
cells inDMEM-FBS (negative control) (Fig. 5Ai;B, lane 1) andSCM
without inhibitors (positive control) (Fig. 5Aii; B, lane 2). When
comparing these two controls, it can againbe seen thatOECsmingle
among astrocytes when not inhibited by the addition of SCM. The
EGFRandPDGFR inhibitors didnot affect SCM-inducedboundary
formation. The inhibitor of the Src family of kinase induced mor-
phological changes in both OECs and astrocytes, but OECs did not
cross into astrocyte domains, suggesting that despite a change in
cellular alignment of the cellular boundary,OECs could notmigrate
within the astrocytic domains. In the presence of the FGFR1 inhibi-
tor, however, the SCM-inducedboundarybetweenOECs andastro-
cytes was disrupted to a certain extent with astrocytic process
stretching into the OEC domains, which appear to interact directly
with OECs (Fig. 5Avi; B, lane 6). Treatment with the FGFR1 inhibi-
tor significantly increased the number of cells that entered the astro-
cytedomain from14.21.5 to23.72.4 cells/300mofboundary
( p 0.01). This value is no longer significantly different from the
number of cells that crossed the boundary in control OEC/astrocyte
confrontation assays (30.22  3.2 cells/300 m of boundary). In
addition, treatment with the tyrosine receptor kinase inhibitors
(EGFR, PDGFR, and FGFR1) did not significantly reduce SCM-
induced astrocyte proliferation, suggesting that the proliferative re-
Figure4. The activity in SCM is trypsin sensitive.A, SDS-PAGEgel stainedwith brilliant blueG-colloidal, showingbreakdownof
a major protein band in SCM after digestion with trypsin-agarose beads. As the factor in SCM is unknown, we were not able to
visualize directly any reduction in band intensity; however, the known 64 kDa protein transferrin was reduced in intensity on
trypsin treatment.B, Digested SCM (SCM tryp)was less potent at inducing astrocyte proliferation (percentage of astrocytes taking
up BrdU in 16 h after treatment). Both SCM- and SCM tryp-treated sets have significantly greater proliferation than control media
(DMEM-BSH/F), but this is significantly different between SCMandSCM-tryp (*p0.05; **p0.001). Error bars represent SEM.
C, Digested SCM was less efficient at promoting boundary formation between astrocytes and OECs. OEC/astrocyte confrontation
assays treatedwithDMEM-FBS (FBS), SCM-50%(SCM), anddigested SCM-50%(SCMtryp) are shown.Astrocytesweredetectedby
GFAP (red), and OECs and Schwann cells were detected by p75 NTR immunoreactivity (green). Arrows show boundaries. Scale bar,
100m.
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sponse was not induced via signaling path-
ways dependent on these receptors
(Fig. 5C).
FGF receptor inhibitor treatment
reduces Schwann cell and OEC plus
SCM-mediated astrocyte area increase
Because the FGFR inhibitor affected
boundary formation, we performed addi-
tional OEC and astrocyte coculture exper-
iments to assess its effect on astrocyte area
as a measurement of astrocyte hypertro-
phy (Fig. 6A,B). The inhibitor was added
either at the time of SCM treatment or 2 d
before immunolabeling in non-SCM-
treated cultures and reapplied every day
for 2 d. Cells were then immunolabeled
for GFAP (astrocytes) and p75NTR (OECs
and Schwann cells) (Fig. 6A), and astro-
cyte areas were measured and quantified
(Fig. 6B). As seen for the confrontation
assays, astrocytes in coculture with
Schwann cells alone and those cultured
with OECs and treated with SCM became
enlarged with an increase in area from
1939 150 m2 (control) to 5286 302
m2 (Schwann cell coculture) and 5524
377 m2 (OEC coculture with SCM). In-
hibition of FGFR1 significantly reduces
this effect, although not to control levels
(OEC coculture with SCMplus FGFR1 in-
hibitor, 2468  396 m2; Schwann cell
coculture plus FGFR inhibitor, 3632 
499 m2). This suggests that both
Schwann cell-induced and OEC/SCM-
induced hypertrophy is mediated in part
via the FGFR1.
The effect of FGF2 on
boundary formation
The FGFR inhibitor data raise the ques-
tion of whether amember of the FGF fam-
ily induces boundary formation in OEC
and astrocyte cocultures. Therefore, we
assessed whether all three glia could re-
spond to FGFs by examining their FGFR
mRNA profile by RT-PCR (Fig. 7A,B).
Astrocytes consistently expressed the
highest levels of FGFR1, FGFR2, and
FGFR3 and therefore expression levels in
OECs and Schwann cells were normalized
to that of astrocytes. None of the glia ex-
pressed FGFR4, and only astrocytes ex-
pressed FGFR3IIIB, but varying levels of
FGFR1, FGFR2, and FGFR3 were seen. Possible differences be-
tween OECs and Schwann cell mRNA levels were seen for
FGFR2IIIB, FGFR2IIIC, and FGFR3IIIC. We also assayed the
levels of FGF2 by ELISA and found that conditioned medium
from OECs, astrocytes, and Schwann cells contained similar lev-
els of FGF2. The ELISA was performed three times, and although
levels were variable between experiments, the average values were
comparable between all three glia, with FGF2 levels of80 pg/ml
detected (Fig. 7C).
Modulation of HSPG expression in confrontation assays
effects boundary formation
Because all three glia secrete FGF2, and the addition of 50 or 100
ng/ml FGF2 was not sufficient to induce boundary formation
(Fig. 8A), we investigated whether FGF2 required activation in
confrontation assays of astrocytes andOECs. Because it is known
that heparin can activate FGF binding to its receptor (Lundin et
al., 2000), heparin was added to confrontation assays between
astrocytes and OECs at days 10–14 after the cells had grown
Figure 5. FGFR1 inhibition prevents OEC/astrocyte boundary formation after SCM treatment but does not influence astrocyte
proliferation. A, Tyrosine kinase inhibitors were applied to OEC/astrocyte (AS) confrontation assays to examine their effects on
SCM-induced boundary formation (boundaries are indicated by white open arrows). Boundaries were not disrupted by the pres-
ence of EGFR and PDGFR inhibitors (inh), although astrocytes became very elongated in the presence of the Src inhibitor. In the
presence of an FGFR1 inhibitor, OECs and astrocytes formed a weaving interlay, with some cell intermingling. Astrocytes were
detectedby their GFAPexpression (red), andOECs andSchwann cellswere labeled for p75 NTR (green).Migrating cells are indicated
with a solidwhite arrow. Scale bar, 200m.B, Quantification of confrontation assays. FGFR1 inhibition increases thenumber (No)
of cellsmigrating into astrocytic territories significantly comparedwith SCM treatment as assessed by the number of cells crossing
a300mboundary. *p0.01.C, AstrocyteproliferationwasassessedbyBrdU incorporationusing indirect immunofluorescence.
Astrocytes were incubated with SCM in the presence or absence of receptor tyrosine kinase (EGFR, PDGFR, and FGFR1) inhibitors,
which had no effect on proliferation. Error bars represent SEM.
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toward each other (Fig. 8Bi–Biv). In these experiments, bound-
ary formation between OECs and astrocytes after the addition of
heparin was promoted in the absence of SCM, and a reduction in
the number of cells crossing boundaries was observed. Further-
more, incubation with the FGFR1 inhibitor in the presence of
heparin increased the number of cells that crossed the boundary,
although levels were not restored to control. These data suggest
that HSPG may be mediating boundary formation in Schwann
cell/astrocyte cultures. For this reason, we treated these cultures
with heparinase or chlorate to disrupt endogenous HSPG levels.
After treatment, Schwann cells could be seen to mingle with as-
trocytes (Fig. 8Av,Avi), suggesting that HSPGs are mediating the
effect.
Interaction of Schwann cells and OECs with astrocytes in the
normal spinal cord
To confirm the physiological relevance of our in vitro findings,
OECs and Schwann cells expressing GFP were injected into op-
posite sides of the spinal cord (Fig. 9). Tissue sections were then
labeled with antibodies against GFP to detect grafted OECs and
Schwann cells, and counterstained against GFAP (blue) or
HSPGs, FGF2, and FGFR1 (red). GFP-expressing OECs were
transplanted into the left-hand side of the spinal cord, and GFP-
expressing Schwann cells were injected into the right-hand side of
the spinal cord. It could be seen that fewer GFAP-positive cells
invaded the Schwann cell graft than the OEC graft (Fig. 9Ai,
Aii,Bi–Biv). The asterisk in Figure 9Aii indicates a larger area
devoid of GFAP-positive astrocytes after Schwann cell injection.
Figure 9, Bv and Bvi (OECs) and Bvii and Bviii (Schwann cells),
illustrates strong immunoreactivity to HSPG in astrocytic pro-
cesses bordering the Schwann cell graft (arrows). Astrocytesmin-
gling in theOEC graft also expressed diffuseHSPG (Fig. 9Bv,Bvi).
Extracellular HSPG immunoreactivity was slightly higher over
the SCgraft (Fig. 9Bvii,Bviii, arrowheads). Both cell grafts showed
increased immunoreactivity to FGFR1 (Fig. 9Ci,Cii, OECs; Cii-
i,Civ, Schwann cells) and FGF2 (Fig. 9Cv,Cvi, OECs; Cvii–Cviii,
Schwann cells) compared with background tissue (Fig. 9C).
SCM and OCM increase astrocyte CSPG
expression, particularly neurocan
The above results indicate that SCM can
influence several features of the astrocyte
stress response, including increases in as-
trocyte area, GFAP expression, and
boundary formation. An additional indi-
cator of the astrocyte stress response is the
upregulation of the inhibitory molecules
from the CSPG family. Astrocytes were
cultured in DMEM-FBS, SCM, or OCM,
or cocultured with Schwann cells. As a
positive control for astrocyte reactivity,
astrocytemonolayers inDMEM-FBSwere
wounded with a pipette tip and immuno-
labeled 24 h later. All cultures were immu-
nolabeled for GFAP and CSPGs, which
were assessed using either a pan-CSPG an-
tibody (CS-56), an antibody that recog-
nizes the DSD-1 epitope embedded in the
CS side chains (473HD), or a neurocan-
specific antibody. All antibodies had
strong immunoreactivity in the positive
wound control in which strongly immu-
noreactive astrocyte processes could be
seen throughout the cultures (Fig. 10Avi) (data only shown for
neurocan). CS-56 immunoreactivity in the negative control
(FBS) was higher than our previous experiments (Lakatos et al.,
2000) (Fig. 10Bi). In the presence of SCM and OCM, expression
of CSPGs using three of the antibodies was higher than FBS con-
trols, although the increases inCSPG induced byOCM treatment
were generally lower (Fig. 10A) (data only shown for neurocan).
However, changes in immunoreactivity were not significantly
different between control FBS-treated astrocytes and cocultures
of astrocyte and Schwann cells (Fig. 10B). The most obvious
changes were found for neurocan expression after both SCM and
OCM treatment, because astrocytes grown in FBS expressed very
little neurocan (Fig. 10Aiv,Av).
To quantify these increases inCSPGexpression inmore detail,
immunoblotting was performed using both pan-CSPG antibod-
ies (CS-56 and 473HD) and the 1G2 antibody (neurocan). Posi-
tive controls were generated by scratching astrocyte monolayers
with a pipette tip. Vinculin was used as a loading control. Before
probing with anti-neurocan, lysates were digested with chon-
droitinase to resolve neurocan into discrete bands for identifica-
tion and quantification (McKeon et al., 1999; Asher et al., 2000).
Both the CS-56 and 473HD antibodies were not suitable for
Western blotting, producing bandswith varying apparentmolec-
ularweights, preventing a comparative analysis (data not shown).
However, full-length neurocan (275 kDa) was identified using
the neurocan antibody (Fig. 10C). Quantification clearly showed
an increase in neurocan expression after SCM treatment (12-
fold) and also after OCM treatment (10.5-fold). Levels were also
elevated in the wound control (10.7-fold). Interestingly, unlike
the immunocytochemistry study, neurocan levels were upregu-
lated after astrocyte coculture with Schwann cells (6.3-fold), sug-
gesting that protein quantification wasmore sensitive. In conclu-
sion, SCM and OCM treatment cause astrocytes to upregulate
expression of neurocan.
To provide an indication of which signaling pathways may
mediate the upregulation of CSPG expression, tyrosine receptor
kinase inhibitors were added to SCM-treated cultures at the time
Figure 6. FGFR1 inhibitor treatment reduces Schwann cell- and OECs plus SCM (OECSCM)-induced hypertrophy. A, Astro-
cytes were cultured alone (Ai) or cocultured with OECSCM (Aii), with OECs plus SCM plus FGFR1 inhibitors (OECSCMFGFR
inh) (Aiii), with Schwann cells (Aiv), or with Schwann cells and FGFR1 inh (Av). The cultures were incubated in various inhibitors
either at the time of SCM addition or 2 d before immunolabeling in the non-SCM-treated cultures and reapplied every day for 2 d.
Cells were immunolabeled for GFAP (astrocytes; red) and p75 NTR (OECs and Schwann cells; green), as well as nuclear staining
(DAPI; blue). Hypertrophic astrocytes are indicated with a white asterisk. Scale bar, 200m. B, Quantification of astrocyte area
using NIH Image analysis, which demonstrates that the FGFR1 inhibitor (inh) can counteract the increase in astrocyte area.
*p 0.02; **p 0.001. Error bars represent SEM.
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of treatment and reapplied every day for 2 d before cultures were
immunolabeled. The addition of the FGFR1 inhibitor had no
effect on SCM-induced expression of either the CS-56 epitope or
neurocan (Fig. 11). Similarly, addition of EGFR and PDGFR in-
hibitors had no effect on CSPG expression in these cultures (data
not shown). This suggests that SCM does not activate essential
FGFR1-, EGFR-, or PDGFR-dependent signals necessary for up-
regulation of CSPGs.
Discussion
In this study, we have shown that SCMadded to cultures of OECs
and astrocytes induces characteristics of reactive astrocytosis.
These characteristics include an increase in astrocyte area, an
increase in GFAP expression, and the formation of a boundary
between the two cell types. This effect was only seen if astrocytes
were in contact with OECs and was not attributable to the addi-
tion of a soluble factor from Schwann cells alone. Furthermore,
our data suggests that the cell contact-dependent induction of
reactive astrocytosis wasmediated in part by FGF2, because it was
susceptible to blockage by an FGFR1 inhibitor. However, this
effect could not be induced by FGF2 alone, either added exog-
enously or when produced constitutively by either OECs or
Schwann cells. When heparin was added to OEC/astrocyte cul-
tures, boundary formation was induced, whereas addition of he-
parinase and chlorate to Schwann cell/astrocyte cultures reduced
boundary formation. This suggests that OECs may secrete a dif-
ferent HSPG profile to Schwann cells and therefore lack the sol-
uble HSPG required for effective FGF-FGFR1 signaling in astro-
cytosis. Although SCM induced the proliferation of astrocytes in
monocultures and increased their CSPG expression, these re-
sponses were not inhibited by the FGFR1 inhibitor. Likewise,
despite CSPG expression and astrocyte proliferation being de-
pendent only on the addition of SCM, the increase in GFAP
expression and astrocytosis required an addition signal from
OEC or Schwann cell contact. Thus, these different characteris-
tics of reactive astrocytosis are mediated by different signaling
events. In vivo studies in which GFP-expressing OECs and GFP-
expressing Schwann cells were injected into the normal spinal
cord provide physiological relevance to the observations made in
vitro of differential intermingling of OECs and Schwann cells
with astrocytes.
CSPG expression and hypertrophy
In this study, the increase in expression of CSPGs in confronta-
tion assays between Schwann cells and astrocytes (using a pan-
antibody, CS-56) was less pronounced than in our previous study
(Lakatos et al., 2000).Despite this, these in vitro assayswere useful
for assessing characteristics of astrocytosis becausemanymarkers
of reactivity, including CSPG expression, were elevated signifi-
cantly in the treated sets above those of control cultures, partic-
ularly in the presence of SCM. The fact that exogenous applica-
tion of SCM to astrocytes produced significant changes in CSPG
expression may reflect a concentration difference between the
SCM and Schwann cell/astrocyte cocultures. These results sug-
gest that the previously reported increase in CSPG expression in
these cocultures (Lakatos et al., 2000)may have beenmediated by
secreted factors rather than being a cell-contact-mediated event.
The CSPG family of proteins have been shown to both inhibit
and elicit neurite outgrowth (Snow et al., 1990; Faissner et al.,
1994). Thismay reflect variability in expression levels or different
properties of the various members of the CSPG family in re-
sponse to CNS injury. For example, after the transplantation of
OECs or Schwann cells into models of spinal cord injury, CSPG
expression was lower around OEC grafts than around Schwann
cell grafts (Takami et al., 2002). However, neurocan expression
was increased to a similar level in response to both glial cells after
injection into the noninjured spinal cord (Asher et al., 2000;
Lakatos et al., 2003). This correlates with our in vitro findings in
which SCM and OCM were able to stimulate neurocan expres-
sion in astrocytes. In contrast, it has been shown that therewas no
change in neurocan expression in response to Schwann cell graft-
ing in a lesion model, despite noticeable changes in CS-56 (Plant
et al., 2001). It is apparent that growth factors can modulate the
cellular expression of individual CSPGs. Recent in vitro studies
demonstrated that addition of EGF or TGF-1 to astrocytes in-
creased expression of phosphacan and neurocan, respectively
(Smith and Strunz, 2005). These data would explain why the
increase in neurocan on astrocytes by OCM and SCM in our
study was not susceptible to FGFR1 inhibition.
Figure 7. OECs, Schwann cells, and astrocytes express mRNA for FGFR1, FGFR2, and FGFR3,
but not FGFR4, and secrete similar levels of FGF2. A, B, RT-PCR was performed for all four FGFR
mRNA isoforms using cDNA synthesized from OECs, Schwann cells, and astrocytes (AS). Levels
were normalized to astrocyte levels (100%), and typical bands with the expected product sizes
are illustrated in B. C, The levels of FGF2 (pg/ml) in SCM, OCM, and ACM were estimated using
ELISA. DMEM-BS lacked FGF2 and was used to collect conditionedmedium from the three glial
cell cultures. Levels were very similar in all conditioned media.
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FGF signaling
In this study, we demonstrated that inhibition of the FGFR1 was
sufficient to reduce astrocyte area, leading to an increase in the
number of OECs that could interdigitate with astrocytic pro-
cesses in the presence of SCM. Therefore, the next step was to
determine whether any of the FGF family members could induce
boundary formation between these cell types. FGF2 is the most
likely candidate, because it is expressed in the brain after birth by
neurons and astrocytes, it binds to FGFR1 (Go´mez-Pinilla et al.,
1995), and it is upregulated after injury, contributing to glial scar
formation (Eddleston and Mucke 1993; Goddard et al., 2002).
FGF2 can also stimulate astrocyte proliferation, hypertrophy,
changes in morphology, and an increase in GFAP expression
(Eclancher et al., 1996; Goddard et al., 2002). However, addition
of FGF2 to OEC/astrocyte cultures did not induce boundary for-
mation; likewise, similar levels of FGF2 were secreted into the
culture medium by both OECs and Schwann cells. These results
do not exclude the possibility that FGF2 is involved in the gener-
ation of boundaries, because it is known that FGF2 requires pre-
sentation to the cell by heparan sulfates for activation. Instead, it
may be that a different repertoire of heparan sulfates is secreted
by Schwann cells and OECs.
We cannot rule out the fact that other members of the FGF
family are involved. The FGF family of growth factors is com-
posed of 23 members, and among them only FGF1, FGF2, FGF9,
and FGF22 are expressed postnatally (Miyamoto et al., 1993;
Beyer et al., 2003; Reuss and von Bohlen und Halbach, 2003).
FGF22 is an unlikely candidate because it is in the same family
grouping as FGF7 and FGF10, which are associated with epithe-
lial cells. It is possible that FGF9 or FGF1 may be exerting the
effect, because both of these FGFs can in-
fluence CNS cells, but there is no evidence
that they play a role in injury, as has been
reported for FGF2 (Eddleston andMucke,
1993; Goddard et al., 2002; Leadbeater et
al., 2006). To get an indication of the FGF
responsiveness of the three different glial
cells, FGFR1–FGFR4 mRNA levels were
determined by RT-PCR. OECs, Schwann
cells, and astrocytes expressed a repertoire
of FGFR1–FGFR3 but lacked the mRNA
for FGFR4. This agrees with the literature,
which has reported FGFR4 expression
only during development (Reuss and von
Bohlen und Halbach, 2003). FGFR1IIIC,
one of the receptors used by FGF2, was
strongly expressed by all three glia. Differ-
ences in the FGFR profile were seen for all
three glial cells, with astrocytes expressing
the highest levels of FGFR1–FGFR3
mRNA. Differential expression for
FGFR2IIIB, FGFR2IIIC, and FGFR3IIIC
were found for OECs and Schwann cells,
supporting the view that they are distinct
glial cells (Barnett et al., 1993; Ramon-
Cueto and Valverde, 1995; Wewetzer et
al., 2002).
The addition of heparin to OEC/astro-
cyte cultures was sufficient to induce
boundary formation. Conversely, the ad-
dition of two reagents that inhibit the
function of HSPG, either by inhibiting HS
sulfation (chlorate) or by digestingHSPGs
directly (heparinases), promoted Schwann cell and astrocyte
mingling. These data suggest that HSPGs are playing a role in
boundary formation. The addition of the FGFR1 inhibitor to-
gether with heparin increased the number of cells crossing the
boundary, but values did not reach control levels, suggesting that
other factors apart fromFGFmay be involved.Heparin, although
well known as an anticoagulant polysaccharide, is also active in
many other biological systems because of its structural similarity
to HS. Heparin andHS have been shown to bind and regulate the
activities of many proteins, including enzymes, growth factors,
ECM (extracellularmatrix) proteins, and the cell surface proteins
of pathogens (for review, see Bernfield et al., 1999). HS is ex-
pressed on the cell surface and in the extracellular matrix of vir-
tually all mammalian cells and is strategically positioned to act as
a cellular regulator of protein function (Guimond et al., 2006).
FGF2 requires activation by heparin/HS through dimerization,
which in turn facilitates FGFR dimerization and transmembrane
signaling (Plotnikov et al., 1999). It has been shown that the level
of sulfation of HSPGs can either positively or negatively regulate
the biological activity of FGF2 (Bashkin et al., 1989; Delehedde et
al., 1996; Lundin et al., 2000). This raises the possibility that
HSPGs secreted by Schwann cells might (1) promote or enhance
the FGF2 signaling response that results in an astrocyte/OEC
boundary or (2) inhibit an endogenous HSPG-dependent
activity that promotes mixing between the cells.
Because treatment with the FGFR1 inhibitor decreased the
size of astrocytes in contact with OECs and therefore reduced the
large physical astrocyte barrier, it is possible that this was suffi-
cient to allowOECs tomigrate among the astrocytes. However, it
was found that the number of cells that crossed this boundarywas
Figure 8. The effect of FGF2, heparin, chlorate, and heparinase on confrontation assays. Ai–Aiv, OEC/astrocyte (AS) confron-
tation assays were incubated in DMEM-FBS (Ai), SCM (Aii), 10 g/ml heparin (Aiii), or FGFR1 inhibitor (inh) (10 M) and 10
g/ml heparin (Aiv). Two days after treatment, the cells were immunolabeled for GFAP (astrocytes; red) and p75 NTR (OECs and
Schwann cells; green). Arrowheads illustrate theboundary.Av,Avi, The additionof chlorate (Av) andheparinase (Avi) to Schwann
cell astrocyte confrontation assays resulted in disruption of the cell boundary. Scale bars: (inAii)Ai–Aiv, 100m; (inAvi)Av,Avi,
50m.B, Quantification of the number (No.) of cells that crossed the boundary. Control (FBS) cultures had the greater number of
cells crossing the boundary, whereas SCM (positive control) treatment gave similar results to heparin treatment, with an increase
inboundary formationanda reduction in thenumber of cells crossing theboundary. Additionof the FGFR1 inhibitor (inh) (SU5402;
10M) increased thenumber of cells crossingboundary distances of 300mbutdid not reach control levels. Addition of FGF2had
no significant effect (N.S., not significant; p 0.01) on the number of cells crossing the boundary. Error bars represent SEM.
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less than that seen in control (non-SCM-
treated) cultures. This suggests that SCM
may also be influencing other aspects of
astrocytosis, such as CSPG expression,
which was FGFR1 independent. In these
experiments, many OECs were able tomi-
grate among astrocytes, suggesting that
the presence of CSPG is unlikely to be a
major determinant, with hypertrophy
playing themore significant role. This is in
contrast to a recent report suggesting that
CSPGs play a critical role in determining
the ability of Schwann cells to enter astro-
cytic areas, using confrontation assays
similar to those used here (Grimpe et al.,
2005). This may highlight another differ-
ence between Schwann cells and OECs, in
that Schwann cell migration may be more
susceptible than OEC migration to CSPG
inhibition, although the role of CSPGs in
OEC/astrocyte interactions still remains
to be determined.
Expression of FGFR1, FGF2, HSPG, and
GFAP after injection into the normal
spinal cord
In this study, we suggest that the FGF2/
FGFR1 system is involved in the astro-
cyte stress response in vitro, which is po-
tentiated by HSPG presented by the
Schwann cells (Fig. 12). To confirm the
physiological relevance of these in vitro
observations, we injected GFP-
expressing OECs and Schwann cells into
the normal spinal cord. Sections were
immunolabeled with antibodies against
FGF2, FGFR1, GFAP, and pan-HSPG,
10 d after the injections. GFAP immu-
noreactivity demonstrated coexistence
of grafted OECs and astrocytes, whereas
grafted Schwann cells did not intermin-
gle with astrocytes. Increased immuno-
reactivity was also found for FGF2 and
FGFR1 over both grafts typical of an in-
jury response (Goddard et al., 2002).
HSPG immunoreactivity was intense in
astrocytic processes lining the border of
the Schwann cell graft, although astro-
cytes within the OEC graft were also im-
munoreactive for HSPG. This is not sur-
prising because the antibody to HSPG
can recognize several HSPGs. Immuno-
reactivity was also seen extracellularly
over both glia grafts, with higher levels
over Schwann cell grafts. It is possible
that there are HSPG differences ex-
pressed between OECs and Schwann
cells that may differentially trigger the
astrocyte stress response. These data are consistent with the
hypothesis that HSPGs secreted by Schwann cells potentiate
the astrocyte stress response. Other reports have shown that
HS can modify the astrocyte stress response after brain injury.
In one study, a small bilateral lesion was made into the rat
sensorimotor cortex, into which Gelfoam soaked in FGF2,
FGF2 plus HS, HS, or saline was applied. After the lesion,
FGF2 and FGFR1 immunoreactivity increased compared with
control groups and was augmented in rats that received FGF2
combined with HS (Go´mez-Pinilla et al., 1995). Furthermore,
Figure 9. GFAP, HSPG, FGFR1, and FGF2 expression after GFP-OEC and GFP-Schwann cell injected into the nonlesioned spinal
cord. GFP (green)-expressing OECs and Schwann cells were injected into parallel sites in the spinal cordwith OECs injected into the
left-hand side and Schwann cells into the right-hand side. The dotted line illustrates these two areas. The arrows represent the
injection site.Ai,Aii, Immunolabeling of freezingmicrotome sectionswith anti-GFP (green) and anti-GFAP (blue) illustrates a lack
of GFAP immunoreactivity and therefore astrocyteswithin the Schwann cell graft (*).Bi–Biv, High-power section fromAi andAii
illustrating themerged (Bi,Biii) GFP (green) and GFAP (blue) and GFAP alone (Bii,Biv) for OECs (Bi,Bii) and Schwann cells (Biii,
Biv). Bv–Bviii, Pan-HSPG antibody (red) immunoreactivity was examined together with GFP (green) and GFAP (blue) for OECs
(Bv) and Schwann cells (Bvii) or GFAP (blue) and HSPG (red) alone for OECs (Bvi) and Schwann cells (Bviii). Arrows denote HSPG
immunoreactivity associated with astrocyte processes lining the Schwann cell grafted cells. Arrowheads point to extracellular
HSPG expression. Bv, Bvi, Astrocytes mingling in the OEC graft also expressed diffuse HSPG. C, Both cell grafts showed increased
immunoreactivity to FGFR1 (Ci, Cii, OECs; Ciii, Civ, Schwann cells; GFP, green; FGFR1, red) and FGF2 (Cv, Cvi, OECs; Cvii, Cviii,
Schwann cells; GFP, green; FGF2, red) compared with background tissue. Scale bars: A, C, 200m; B, 50m.
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a more detailed study of the intracellular dynamics of FGFR1,
FGF2, and HSPGs after a lesion in the rat cerebral cortex
suggests that HSPGs regulate FGF2 storage, nuclear traffick-
ing, and cell-specific injury responses in CNS wounds (Lead-
beater et al., 2006). In this study, a similar low level of HSPG
expression was seen in the normal CNS
before injury as we found in the spinal
cord. These data support the hypothesis
that differential expression of HSPGs by
OECs and Schwann cells can influence
the formation of a boundary between
these cells and astrocytes.
Implications for transplantation
strategies to promote CNS repair
The potential cellular interactions that
take place after cell transplantation are
complex. This can be seen by the in vitro
assays used in this study, in which several
secreted and contact-mediated factors in-
terplay in the induction of the astrocytic
stress response. A better understanding of
the mechanisms by which Schwann cells
induce astrocyte reactivity could allow us
to reduce the growth-inhibitory response
and thus improve repair after glial cell
transplantation. This would not only be
beneficial for strategies involving the
transplantation of Schwann cells, but also
for other injury scenarios, because it has
been well documented that after the dis-
ruption of the glia limitans, Schwann cells
from the dorsal root are able to invade the
CNS environment of the spinal cord
(Franklin and Blakemore, 1993; Bruce et
al., 2000; Ramer et al., 2004; Boyd et al.,
2005), where they may add to the inhibi-
tory nature of the glial scar. Furthermore,
in the situation in which OECs are trans-
planted into the injured CNS to promote
repair, the infiltrating Schwann cells may
then promote the reactive phenotype in
astrocytes that are in contact with the
grafted OECs. Identification of factors se-
creted by Schwann cells that induce this
response in astrocytes whether these cells
have been transplanted with the intent of
promoting repair or result from endoge-
nous invading populations would further
our ability to enhance the growth-
promoting properties of the astrocyte-rich
environment.
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